patients with coronary artery disease undergoing non-intermediate thoracic tumor surgery
Conditions
Interventions
µFR>=0.75 group:None
µFR14% and IVUS images indicate the presence of calcified plaques with absence of calcified nodules:None
µFR14% and IVUS images indicate non-calcified, calcified nodules or hypoechoic plaques:None
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. age>=18 years old; 2. patients with thoracic tumor planned for non-intermediate thoracic surgery (lung tumor cStage I-III planned for anatomical lobectomy, or mediastinal tumor cStage I-III); 3. coronary CTA showing severe stenosis (>=70% diameter stenosis) in an epicardial coronary artery with >=2.5 mm reference diameter, or exercise treadmill test positive, or with clinically suspect angina symptoms with at least one ASCVD risk factor (LDL-C =4.9 mmol/L; history of prior PCI; diabetes mellitus; hypertension; CKD stage 3-4; smoking); 4. patients agree to undergo invasive coronary angiography examination; 5. life expectancy >=1 year; 6. able to understand and agree to the trial protocol, and provide informed written consent; 7. with >= 1 lesion of 50% to 90% diameter stenosis and reference lumen diameter >= 2.5 mm by visual assessment, and the lesion is eligible for PCI.
Exclusion criteria
Exclusion criteria: 1. prior history of CABG; 2. prior history of PCI within 3 months; 3. prior history of acute myocardial infarction within 3 months; 4. severe heart valve disease; 5. severe heart failure with LVEF =2.5 mm; chronic total occlusion; unprotected left main coronary artery disease; severely calcified lesion; ostial lesions of a major epicardial coronary artery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| perioperative major adverse cardiovascular events (a composite of cardiac death, non-fatal myocardial infarction, unplanned revascularization, non-fatal stroke, and congestive heart failure);perioperative myocaridal injury;perioperative new-onset arrhythmias; | — |
Secondary
| Measure | Time frame |
|---|---|
| major adverse cardiovascular events (a composite of cardiac death, non-fatal myocardial infarction, unplanned revascularization, non-fatal stroke, and congestive heart failure) 30 days after surgery;Major adverse cardiovascular events (a composite of cardiac death, non-fatal myocardial infarction, unplanned revascularization, non-fatal stroke, and congestive heart failure) 6-months after surgery;perioperative bleeding; procedure time of thoracic surgery;all-cause mortality;morphological progress of lung tumor;cost-effectiveness; | — |
Countries
China
Contacts
Public ContactWenzheng Han
Shanghai Chest Hospital
Outcome results
None listed